Home › Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer clinical trials recruiting in the U.S.
429 studies for Non-Small Cell Lung Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX145 studies
- New York City, NY120 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH56 studies
- Washington, DC55 studies
- Seattle, WA53 studies
- Dallas, TX52 studies
- Tampa, FL51 studies
- Philadelphia, PA51 studies
- Queens, NY49 studies
- Pittsburgh, PA48 studies
- San Diego, CA48 studies
- Atlanta, GA47 studies
- Edison, NJ47 studies
- Portland, OR46 studies
- Santa Monica, CA45 studies
- Grand Rapids, MI44 studies
- Orlando, FL44 studies
- Detroit, MI44 studies
- Cleveland, OH43 studies
- New Haven, CT41 studies
- Durham, NC39 studies
- Jacksonville, FL39 studies
- Rochester, MN37 studies
- Baldwin Park, CA36 studies
- San Francisco, CA36 studies
- Cincinnati, OH35 studies
- Indianapolis, IN32 studies
- Kansas City, MO31 studies
- Miami, FL31 studies
- Salt Lake City, UT31 studies
- Aurora, CO30 studies
- Austin, TX30 studies
By state
- Alabama36 studies
- Alaska11 studies
- Arizona66 studies
- Arkansas34 studies
- California207 studies
- Colorado73 studies
- Connecticut55 studies
- Delaware21 studies
- District of Columbia38 studies
- Florida155 studies
- Georgia73 studies
- Hawaii10 studies
- Idaho18 studies
- Illinois94 studies
- Indiana49 studies
- Iowa29 studies
- Kansas34 studies
- Kentucky46 studies
- Louisiana26 studies
- Maine16 studies
- Maryland76 studies
- Massachusetts102 studies
- Michigan101 studies
- Minnesota69 studies
- Mississippi20 studies
- Missouri86 studies
- Montana18 studies
- Nebraska40 studies
- Nevada25 studies
- New Hampshire17 studies
- New Jersey88 studies
- New Mexico22 studies
- New York169 studies
- North Carolina79 studies
- North Dakota15 studies
- Ohio121 studies
- Oklahoma31 studies
- Oregon60 studies
- Pennsylvania103 studies
- Rhode Island13 studies
- South Carolina30 studies
- South Dakota20 studies
- Tennessee118 studies
- Texas204 studies
- Utah56 studies
- Vermont7 studies
- Virginia137 studies
- Washington84 studies
- West Virginia14 studies
- Wisconsin45 studies
Recently updated studies
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06623422Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT02146170Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06472245A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07293247The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07680764Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07751042A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07365319A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06265285Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06918132A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06780085A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07513376A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07189871A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07090499Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07388524A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07155187Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06625775A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06907615A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07554339A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07190248From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.